New River Pharmaceuticals — Technical Presentation (June 2006)
8 slides from New River Pharmaceuticals's technical presentation, Jun 20, 2006
Slide 1: Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104)
Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104) Jasinski, D.R.1; Krishnan, S.2 1 Medicine, Johns Hopkins University, Baltimore, MD, USA.;2 New River Pharmaceuticals Inc., Blacksburg, VA, USA NRP lisdexamfetamine dimesylate (LDX) NRP104 • Pharmacologically inactive pro-drug in which d-
Slide 2: Systolic Blood Pressure
Do you like the drug effect you are feeling now? Systolic Blood Pressure
Slide 3: Mean Score
Mean Score Mean Score’ Placebo d-amphetamine 10mg _ NRPI04 26 mg
Slide 4: Treatment Enjoyment Assessment and Cohort 1 Findings
Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104) Jasinski, D.R.1; Krishnan, S.2 1 Medicine, Johns Hopkins University, Baltimore, MD, USA.;2 New River Pharmaceuticals Inc., Blacksburg, VA, USA NEW RIVER PROTOCOL NRP104.A02 TREATMENT ENJOYMENT ASSESSMENT QUESTIONNAIRE DRUG CHOSEN TO TAKE
Slide 5: Mean d-amphetamine Concentration-Time
PK data Cohort 2 Mean d-amphetamine Concentration -Time Plots
Slide 6: Systolic Blood Pressure
Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104) Jasinski, D.R.1; Krishnan, S.2 1 Medicine, Johns Hopkins University, Baltimore, MD, USA.;2 New River Pharmaceuticals Inc., Blacksburg, VA, USA Do you like the drug effect you are feeling now? Systolic Blood Pressure
Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104) Jasinski, D.R.1; Krishnan, S.2 1 Medicine, Johns Hopkins University, Baltimore, MD, USA.;2 New River Pharmaceuticals Inc., Blacksburg, VA, USA Analysis of Maximum Effect Based upon ANOVA Dependent Variable Do you like the drug effect you